Pharmacogenetics May Prevent Psychotropic Adverse Events in Autism Spectrum Disorder: An Observational Pilot Study.

ABSTRACT:

Introduction

Up to 73% of individuals with autism spectrum disorder (ASD) and intellectual disability (ID) currently have prescriptions for psychotropic drugs. This is explained by a higher prevalence of medical and psychiatric chronic comorbidities, which favors polypharmacy, increasing the probability of the appearance of adverse events (AEs). These could be a preventable cause of harm to patients with ASD and an unnecessary waste of healthcare resources.

Objective

To study the impact of pharmacogenetic markers on the prevention of AE appearance in a population with ASD and ID.

Methods

This is a cross-sectional, observational study (n = 118, 72 participants completed all information) in the ASD population. Sociodemographic and pharmacological data were gathered. The

SUBMITTER: de Miguel L 

PROVIDER: S-EPMC10610471 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature